RxDoctor Payments Data

Romana Zar

Geriatric Medicine · Hartford, CTNPI 1992978001

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Pfizer at 52.5% of the total.

$154in general payments, 2019–2025

Across 9 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$81
  • Amgen$40
  • Boehringer Ingelheim$18
  • AstraZeneca$15

What the payments were for

  • Food & beverage$154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer5$81
Amgen2$40
Boehringer Ingelheim1$18
AstraZeneca1$15

How this compares

$154 in reported general payments places this provider in the 65th percentile of 84 geriatric medicine providers in Connecticut.

See all geriatric medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$235,821
Medicare patients
592
Services billed
3,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$69,994
EliquisApixaban57$61,074
RybelsusSemaglutide42$50,984
OzempicSemaglutide26$36,583
MyrbetriqMirabegron39$29,759
ProliaDenosumab17$28,984
JanuviaSitagliptin Phosphate30$28,057
TrulicityDulaglutide13$26,034
XareltoRivaroxaban13$20,979
Atorvastatin Calcium729$8,598
Levothyroxine Sodium745$8,401
Rosuvastatin Calcium364$6,922
JanumetSitagliptin Phos/Metformin Hcl12$6,554
SynthroidLevothyroxine Sodium79$5,625
Losartan Potassium434$4,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$18$69,99456 claims
PfizerEliquis, Premarin$81$63,24969 claims
AmgenProlia$40$28,98417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 84 geriatric medicine providers in Connecticut.

Other geriatric medicine in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →